Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction The CHECK-HF Registry

Hans-Peter Brunner-La Rocca*, Gerard C. Linssen, Frank J. Smeele, Annemarie A. van Drimmelen, Henk-Jan Schaafsma, Paul H. Westendorp, Philip C. Rademaker, Hendrik J. van de Kamp, Arno W. Hoes, Jasper J. Brugts, CHECK-HF Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

112 Citations (Web of Science)


OBJECTIVES This study investigated adherence to drug therapy guidelines in heart failure (HF) with reduced left-ventricular ejection fraction (LVEF) of

BACKGROUND Despite previous surveys of HF, important uncertainties remain regarding guideline adherence in a representative real-world population.

METHODS A cross-sectional registry in 34 Dutch HF outpatient clinics that included 10,910 patients with the diagnosis of HF was examined. Of that number, 8,360 patients had LVEF

RESULTS In the HFrEF group, 81% of the patients were treated with loop diuretics, 84% with renin-angiotensin-system (RAS) inhibitors, 86% with beta-blockers, 56% with mineralocorticoid-receptor antagonists (MRA), and 5% with I-f-channel inhibition. Differences in medication use were minor among the 3 groups but were significant among centers. Inability to tolerate the medications was recorded in 9.4% patients taking RAS inhibitors, 3.3% taking beta-blockers, and 5.4% taking MRAs. Median loop diuretic dose was 40 mg of furosemide equivalent, RAS inhibitor dose 50% of target, beta-blocker dose 25% of target, and MRA dose 12.5 mg of spironolactone equivalent. Elderly patients were treated predominantly with diuretics and less often with RAS inhibitors, beta-blockers, and MRAs.

CONCLUSIONS This large contemporary HF registry showed a relatively high use of evidence-based treatment, particularly in younger patients. However, the average dose of evidence-based medication was still lower than recommended by guidelines. Furthermore, the more recently introduced I-f-channel inhibition has hardly been adopted. There is ample room for improvement of HFrEF therapy, even more than 25 years after convincing evidence that HFrEF treatment leads to better outcome. (C) 2019 by the American College of Cardiology Foundation.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalJACC: Heart Failure
Issue number1
Publication statusPublished - Jan 2019


  • ESC
  • HFrEF
  • guideline adherence
  • heart failure
  • reduced ejection fraction
  • registry
  • treatment

Cite this